Published on : May 12, 2017
Albany, New York, May 12, 2017: Interstitial Cystitis is a chronic painful bladder syndrome that is rising immensely from last few years and the major risk factors that contribute towards it are age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. To provide a more in-depth analysis, Market Research Hub (MRH) has recently added a new report titled as “Interstitial Cystitis - Pipeline Review, H1 2017” to its vast database. The report provides a comprehensive information on the Interstitial Cystitis and its pipeline analysis by companies involved in its therapeutic development.
Interstitial cystitis is medical condition in which person experience bladder pain, bladder pressure and sometimes pelvic pain, ranging from mild discomfort to severe pain. The major symptoms include decreased bladder capacity, chronic pelvic pain, painful sexual intercourse, and a persistent, urgent need to urinate. The major treatment is non-steroidal anti-inflammatory drug, antidepressants, and antihistamines. Basically, bladder is a hollow, muscular organ that stores urine, it expands until it's full and then signals your brain that it's time to urinate. With interstitial cystitis problem, these signals get mixed up and a feeling to urinate more often and with smaller volumes occur.
The report initiates with the overview of Interstitial Cystitis and its therapeutics development. Further, the pipeline overview, pipeline companies, and products under development by companies is detailed. The Interstitial Cystitis therapeutics assessment is completed by the target, mechanism of action, route of administration and molecule type. Moreover, the research has also listed the main companies involved in therapeutics development of interstitial cystitis along with featured dormant and discontinued projects. The top players analyzed and listed in the research includes Allergan Plc, Aquinox Pharmaceuticals Inc., Astellas Pharma Inc., BELLUS Health Inc., Kytogenics Pharmaceuticals Inc., Lipella Pharmaceuticals Inc., Merck & Co Inc., UCB SA, Urigen Pharmaceuticals Inc. and Xigen SA.
The detailed study further profiles the interstitial cystitis drug which includes product description, mechanism of action and R&D process, the drug listed under the report are Heparin + lidocaine hydrochloride, ASP-6294, BLU-5937, AF-219, AQX-1125, brimapitide, certolizumab pegol, F-16357, GM-0111, lidocaine hydrochloride, LP-08, onabotulinumtoxinA, onabotulinumtoxinA SR, mesalamine, pentosan polysulfate sodium, and URG-801.
Lastly, the news and press release that may further enhance your knowledge and outlook towards the interstitial cystitis is linked along with various primary and secondary research. The present guide is a complete repository of information, built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068015
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-866-997-4948US Toll Free
Email : firstname.lastname@example.org